Resveratrol Reduces C-reactive Protein and Cholesterol in Schizophrenia

Patients with schizophrenia (SZ) are generally found with overweight and obesity and several metabolic disorders. Additionally these patients have less life expectancy, with cardiovascular disease (CVD) the main cause of increased mortality in these patients. This is a case-report study of a male, 46 years old, with Diagnosis of SZ following a 1-month resveratrol supplementation program. In summary, we observed association of resveratrol supplementation (200 mg/day) with reduced C-reactive protein (CRP), and reduced cholesterol and triglycerides. The benefits included the improvement in Framingham score and mean reduction of 3% of risk of a heart attack over the next 10 years.